Colorectal cancer prevention in Europe: burden of disease and status of screening programs, Prev Med. mai, vol.62, pp.132-173, 2014. ,
Global patterns and trends in colorectal cancer incidence and mortality, Gut, vol.66, issue.4, pp.683-91, 2017. ,
Adenoma--carcinoma sequence or « de novo » carcinogenesis? A study of adenomatous remnants in a population-based series of large bowel cancers, Cancer. 15 févr, vol.69, issue.4, pp.883-891, 1992. ,
,
Association Between Time to Colonoscopy After a Positive Fecal Test Result and Risk of Colorectal Cancer and Cancer Stage at Diagnosis, JAMA. 25 avr, vol.317, issue.16, pp.1631-1672, 2017. ,
Lower risk of ,
European guidelines for quality assurance in colorectal cancer screening and diagnosis: overview and introduction to the full supplement publication ,
, Endoscopy, vol.45, issue.1, pp.51-60, 2013.
Comparison between a guaiac and three immunochemical faecal occult blood tests in screening for colorectal cancer, Eur J Cancer, vol.48, issue.16, pp.2969-76, 2012. ,
Reduction in colorectal cancer mortality by fecal occult blood screening in a French controlled study, Gastroenterology. juin, vol.126, issue.7, pp.1674-80, 2004. ,
Survival of colorectal cancer patients in Europe during the period 1978-1989, European Journal of Cancer. 1 déc, vol.34, issue.14, pp.2176-83, 1998. ,
Time from positive screening fecal occult blood test to colonoscopy and risk of neoplasia, Dig Dis Sci, vol.54, issue.11, pp.2497-502, 2009. ,
Quantitative fecal immunochemical tests for colorectal cancer screening, Int J Cancer, vol.15, issue.2, pp.234-278, 2018. ,
Immunochemical faecal occult blood test: number of samples and positivity cutoff. What is the best strategy for colorectal cancer screening?, Br J Cancer. 27 janv, vol.100, issue.2, pp.259-65, 2009. ,
Performance of ,
URL : https://hal.archives-ouvertes.fr/inserm-00421655
Long-term effect of faecal occult blood screening on incidence and mortality from colorectal cancer, Dig Liver Dis. déc, vol.46, issue.12, pp.1121-1126, 2014. ,
Colorectal cancer screening adherence is higher with fecal immunochemical tests than guaiac-based fecal occult blood tests: a randomized, controlled trial, Prev Med. juin, vol.50, issue.5-6, pp.297-306, 2010. ,
Screening for colorectal cancer: comparison of perceived test burden of guaiac-based faecal occult blood test, faecal immunochemical test and flexible sigmoidoscopy, Eur J Cancer. juill, vol.46, issue.11, pp.2059-66, 2010. ,
Screening for colorectal cancer: random comparison of guaiac and immunochemical faecal occult blood testing at different cut-off levels, Br J Cancer. 7 avr, vol.100, issue.7, pp.1103-1113, 2009. ,
, Institut National du Cancer. Les cancers en France en 2018 -L'essentiel des faits et chiffres (édition, 2019.
, Violaine Randrian -Thèse de Médecine -13 septembre, 2019.
Quality Metrics of a Fecal Immunochemical Test-Based Colorectal Cancer Screening Program in Korea, Gut Liver. 15 mars, vol.12, issue.2, pp.183-192, 2018. ,
Fecal immunological blood test is more appealing than the guaiac-based test for colorectal cancer screening. Dig Liver Dis, vol.49, pp.1267-72, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01620339
Time to Colonoscopy and Risk of Colorectal Cancer in Patients With Positive Results From Fecal Immunochemical Tests, Clin Gastroenterol Hepatol. juin, vol.17, issue.7, pp.1332-1340, 2019. ,
, The cost
The somatic mutation landscape of premalignant colorectal adenoma, Gut, vol.67, issue.7, pp.1299-305, 2018. ,
,
A pooled analysis of advanced colorectal neoplasia diagnoses after colonoscopic polypectomy ,
, Gastroenterology. mars, vol.136, issue.3, pp.832-873, 2009.
Consequences of Increasing Time to Colonoscopy Examination After Positive Result From Fecal Colorectal Cancer Screening Test, Clin Gastroenterol Hepatol, vol.14, issue.10, pp.1445-1451, 2016. ,
, , 2018.
, Violaine Randrian -Thèse de Médecine -13 septembre, 2019.
,
The impact of the ,
URL : https://hal.archives-ouvertes.fr/hal-00478264
Additional mailing phase for FIT after a medical offer phase: The best way to improve compliance with colorectal cancer screening in France. Dig Liver Dis, Mars, vol.49, issue.3, pp.308-319, 2017. ,
URL : https://hal.archives-ouvertes.fr/hal-01537821
Test immunochimique de recherche de sang occulte dans les selles, Détermination d'un seuil de positivité pour démarrer les projets de démonstration du PQDCCR ISSN ,
Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer ,
, Gastroenterology, vol.152, issue.5, pp.1217-1237, 2017.
Nutrients, foods, and colorectal cancer prevention ,
, , vol.148, pp.1244-1260, 2015.
,
, Br J Cancer, vol.101, issue.8, pp.1274-81, 2009.
Earlier stages of colorectal cancer detected with immunochemical faecal occult blood tests, Neth J Med. mai, vol.67, issue.5, pp.182-188, 2009. ,
,
,
, Colorectal cancer screening: Systematic review of screen-related morbidity and mortality
, Cancer Treat Rev. mars, vol.54, pp.87-98, 2017.
,
Lagtimes in diagnosis and treatment of colorectal cancer: determinants and association with cancer stage and survival, Aliment Pharmacol Ther, vol.28, issue.9, pp.1166-74, 2008. ,
, Relance, vol.2, p.14
, Coloscopie non réalisée, vol.331, issue.7, p.14
, 51%) Hommes 401 (73,99%) 321 (47,49%) Âge moyen (min-max, Coloscopie réalisée 542 (63,0%) 676 (92,86%) Femmes 141 (26,01%), vol.52, pp.50-72
, Relance 2 358 (30,28%) 278 (28,93%)
, Coloscopie non réalisée, vol.430, issue.10, p.41
, 22%) 408 (47,39%) Hommes 529 (76,77%) 453 (52,61%) Âge moyen (min-max, Coloscopie réalisée 689 (58,29%) 861 (89,59%) Femmes 160, vol.61, p.82
, 52%) Femmes 1613 (48,08%) 1193(46,80%) Hommes 1742 (51,92%) 1356 (53,20%) Âge moyen (min-max, 20) Relance, vol.62, issue.2, p.2028
, Coloscopie non réalisée 1175 (35,02%), p.7
, Mon premier souci sera de rétablir, de préserver ou de promouvoir la santé dans tous ses éléments, physiques et mentaux, individuels et sociaux
, Je respecterai toutes les personnes, leur autonomie et leur volonté, sans aucune discrimination selon leur état ou leurs convictions. J'interviendrai pour les protéger si elles sont affaiblies, vulnérables ou menacées dans leur intégrité ou leur dignité. Même sous la contrainte
, Admis(e) dans l'intimité des personnes, je tairai les secrets qui me seront confiés